Overview

Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study

Status:
Unknown status

Trial end date:
2020-08-01

Target enrollment:

Participant gender:

Summary

This is a phase II randomized clinical trial to study the effect of COX-2 inhibitor Celecoxib and EGFR tyrosine kinase inhibitor Erlotinib alone or in combination on molecular markers of apoptosis and angiogenesis.

Phase:

Phase 2

Details

Lead Sponsor:

Tata Memorial Hospital

Treatments:

Celecoxib
Erlotinib Hydrochloride